References
- Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
- Persky DO, Unger JM, Spier CM, . Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–2263.
- Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004;22:2982–2984.
- Recher C, Coiffier B, Haioun C, . Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858–1867.
- Yahalom J. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. J Clin Oncol 2010;28:4105–4107.
- Yang WS. Pilot trial of yttium-90-ibritumomab tiuxetan consolidation following R-CHOP chemotherapy in patients with limited-stage, bulky diffuselarge B-cell lymphoma. Leukemia and Lymphoma, 2012.
- Zinzani PL, Tani M, Fanti S, . A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769–773.
- Pfreundschuh M, Ziepert M, Reiser M, The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade non-Hodgkin-Lymphoma Study Group for elderly patioents with DLBCL. Blood 112, 2008
- Phan J, Mazloom A, Jeffrey Medeiros L, . Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170–4176.
- Wirth A. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2007;48:2121–2136.
- Zelenetz AD, J.S. A, R.H. A, . Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2011;9:484–560.
- Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med 2000;41: 297–308.
- Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin's lymphoma: from the “magic bullets” to “radioactive magic bullets”. Yale J Biol Med 2011;84:391–407.
- Rizvi SN, Visser OJ, Vosjan MJ, . Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using (89)Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging 2012;3:512–520.
- Witzig TE, Fishkin P, Gordon LI, . Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011;52:1188–1199.
- Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res 2011;17:6112–6117.